Entrada Therapeutics, Inc.

Entrada Therapeutics, Inc. (NASDAQ: TRDA) is a clinical-stage biopharmaceutical company focused on developing a novel class of genetic medicines designed to treat intracellular diseases previously considered inaccessible to therapeutic intervention. The company's website is www.entradatx.com.

The company's core innovation is its proprietary Endosomal Escape Vehicle (EEV) platform, a versatile delivery technology based on small cyclic peptides that enable efficient intracellular delivery of highly targeted therapeutics. The EEV platform addresses a fundamental challenge in drug development: approximately 75 percent of disease-causing targets are located inside cells, yet most therapeutic approaches struggle to penetrate cell membranes and escape endosomal compartments. Entrada's EEV peptides bind to cell membranes at normal serum pH to trigger endocytosis, then leverage pH-dependent mechanisms to escape early endosomes and deliver therapeutic payloads to intracellular targets. Preclinical studies indicate that greater than 90 percent of EEV-conjugated material is taken up by body tissues, with approximately 50 percent reaching intended intracellular targets compared to less than 2 percent for conventional biologics.

Entrada's clinical development pipeline focuses primarily on neuromuscular diseases, particularly Duchenne muscular dystrophy (DMD), where the company is advancing four clinical-stage programs: ENTR-601-44, ENTR-601-45, ENTR-601-50, and ENTR-601-51. These candidates are EEV-conjugated phosphorodiamidate morpholino oligomers (PMOs) designed to promote exon skipping and restore functional dystrophin production. The company estimates over 11,500 patients in the U.S. and Europe carry mutations amenable to its current exon-skipping programs.

Beyond neuromuscular disease, Entrada is expanding into ocular therapeutics with ENTR-801, an oligonucleotide-based therapy for Usher syndrome type 2A affecting approximately 14,000 to 15,000 patients in the U.S. and Europe.

The company also maintains a strategic partnership with Vertex Pharmaceuticals for VX-670, an EEV-based therapeutic candidate for myotonic dystrophy type 1. Under this collaboration, Entrada received an initial $250 million in upfront payments and equity investment, with additional milestone payments triggered by clinical advancement.